School of Medicine
Showing 1-20 of 143 Results
-
William Alegria
Lecturer, Medicine - Med/Infectious Diseases
BioDr. Alegria is a board-certified Infectious Diseases Pharmacotherapy specialist and antimicrobial stewardship consultant with the Stanford Antimicrobial Safety and Sustainability Program. He primarily practices in the inpatient setting and is dedicated to developing targeted stewardship interventions in immunocompromised patient populations. His clinical interests include management of infections in immunocompromised hosts, antifungal pharmacotherapy, and difficult-to-treat infections.
Publications (selected)
Navigating recurrent Clostridioides difficile infection without Bezlotoxumab: potential challenges ahead. Arya R, Zimmet AN, Holubar M, Alegria W. Antimicrob Steward Healthc Epidemiol. 2025
How to leverage medication use evaluations for antimicrobial stewardship goals: a primer for physicians. Prasad R, Arya R, Meng L, Holubar M, Alegria W, Zimmet AN.
Antimicrob Steward Healthc Epidemiol. 2025
Beyond the basics: rethinking antimicrobial stewardship by targeting cytomegalovirus immune globulin for immunocompromised patients. Prasad R, Lu B, Veloria D, Mui E, Nelson J, Dhillon G, Deresinski S, Holubar M, Alegria W. Antimicrob Steward Healthc Epidemiol. 2025
No "One-Size-Fits All": chronic "Carryover" diagnoses dilute antibiotic prescribing rates for sinusitis among adults in primary and urgent care settings. Smith M, Hawkins M, Laikijrung C, Mui E, Alegria W, Leung T, Zimmet A, Ha D, Holubar M. Infect Control Hosp Epidemiol. 2024
Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience. Lu B, Ha D, Shen S, Ferguson Toll J, Kim A, Kim S, Mui E, Deresinski S, Holubar M, Alegria W. Open Forum Infect Dis. 2024
"Electronic Phenotyping" Antimicrobials to Facilitate Outpatient Stewardship for Asymptomatic Bacteriuria and Urinary Tract Infection in Renal Transplant. Zimmet AN, Ha D, Mui E, Smith M, Hawkins M, Alegria W, Holubar M. Open Forum Infect Dis. 2024
Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia. Fox E, Ha D, Bounthavong M, Meng L, Mui E, Holubar M, Deresinski S, Alegria W. BMC Infect Dis. 2022
Shorter durations of antibiotic therapy in organ transplant. Alegria W, Medvedeva N, Holubar M. Curr Opin Organ Transplant. 2022
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM. Br J Haematol. 2022
Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia. Alegria W, Marini BL, Gregg KS, Bixby DL, Perissinotti A, Nagel J. J Natl Compr Canc Netw. 2022
Effect of rapid methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction screening on vancomycin use in the intensive care unit. Diep C, Meng L, Pourali S, Hitchcock MM, Alegria W, Swayngim R, Ran R, Banaei N, Deresinski S, Holubar M. Am J Health Syst Pharm. 2021 Dec
The Current State of Antifungal Stewardship in Immunocompromised Populations. Alegria W, Patel PK. J Fungi (Basel). 2021
Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches. Holubar M, Meng L, Alegria W, Deresinski S. Infect Dis Clin North Am. 2020
Impact of Rapid Antimicrobial Susceptibility Testing in Gram-Negative Rod Bacteremia: a Quasi-experimental Study. Hogan CA, Ebunji B, Watz N, Kapphahn K, Rigdon J, Mui E, Meng L, Alegria W, Holubar M, Deresinski S, Banaei N. J Clin Microbiol. 2020
Antimicrobial Stewardship in Cancer Patients: The Time is Now. Aitken SL, Nagel JL, Abbo L, Alegria W, Barreto JN, Dadwal S, Freifeld AG, Jain R, Pergam SA, Tverdek FP, Seo SK; Antimicrobial Stewardship in Cancer Consortium ASCC. J Natl Compr Canc Netw. 2019 -
Jason Andrews
Professor of Medicine (Infectious Diseases) and, by courtesy, of Epidemology
Current Research and Scholarly InterestsOur laboratory aims to develop and test innovative approaches to the diagnosis, treatment and control of infectious diseases in resource-limited settings. We draw upon multiple fields including mathematical modeling, microbial genetics, field epidemiology, statistical inference and biodesign to work on challenging problems in infectious diseases, with an emphasis on tuberculosis and tropical diseases.
-
Florian Bach
Postdoctoral Scholar, Infectious Diseases
BioI'm a molecular infection biologist by training, but shifted my focus from pathogens to hosts for my graduate research. During my PhD with Phil Spence in Edinburgh I studied both falciparum and vivax malaria using controlled human (re)infection models, collaborating closely with the groups of Simon Draper and Angela Minassian in Oxford. As a hybrid bioinformatician and experimentalist, I love systems immunology for answering complex questions about human health. For my postdoc, I study in how the human immune response to malaria evolves in infants as they become reinfected and age. I'm also interested in how such early-life immunological events, malaria and beyond, may affect vaccine responses and immune development later in life. I address this question by making use of a longitudinal study cohort of infants receiving monthly chemoprevention in Eastern Uganda, together with our collaborators at UC San Francisco and IDRC Uganda.
-
Niaz Banaei
Professor of Pathology and of Medicine (Infectious Diseases)
Current Research and Scholarly InterestsHis research interests include (1) development, assessment, and improvement of novel infectious diseases diagnostics, (2) enhancing the quality of C. difficile diagnostic results, and (3) characterization of M. tuberculosis virulence determinants.
-
Brian Blackburn
Clinical Professor, Medicine - Infectious Diseases
Current Research and Scholarly InterestsMy interests include parasitology and global health; I've investigated cryptosporidium and angiostrongylus outbreaks; schistosoma/strongyloides seroprevalence in refugees, and the distribution and impact of ITNs for malaria and filariasis prevention in Nigeria and India. I have done clinical and programmatic work at teaching hospitals in Liberia and Bangladesh and have opportunities for research in Bangladesh and Kenya, in collaboration with ICDDR,B and CDC, Kenya
-
Catherine Blish
George E. and Lucy Becker Professor in Medicine
Current Research and Scholarly InterestsThe major goal of our research is to gain insight into the prevention and control of HIV and other viral pathogens by studying the interplay between the virus and the host immune response. We investigate the role of various arms of the immune response, but with a particular focus on NK cells. We hope to gain additional insights into control of infectious diseases by studying how pregnancy modulates immune responses.
-
Paul Bollyky
Professor of Medicine (Infectious Diseases) and of Microbiology and Immunology
Current Research and Scholarly InterestsBacteriophages, viruses that infect bacteria, are abundant in the human body. However, their contributions to human health and disease are largely unknown. The Bollyky Lab
studies interactions between phages and both their human and bacterial hosts with the goal of developing innovative strategies to improve human health. -
Hector Fabio Bonilla
Clinical Professor, Medicine - Infectious Diseases
BioAs a young physician at Louisiana State University, Dr. Bonilla focused on the Clinical Management of HIV/AIDS and HCV, two neglected and stigmatized diseases for which effective therapies were in their infancy. While learning the clinical aspects of the two diseases, Dr. Bonilla saw a need to create and organize a support community to promote understanding and management of the conditions. Subsequently, he went to Summa Health System in Akron, Ohio, and he continued his work where he specialized in HIV/HCV as well as in Infectious Diseases Clinical Practice. In addition to teaching medical residents and students, Dr. Bonilla participated in numerous clinical trials and developed clinical research projects. Furthermore, he led the Infection Renal Transplant Program, HIV and HCV clinics, and he participated in several cooperative studies with Case Western Reserve University. Dr. Bonilla’s interest in academia led him to the University Of Pittsburgh Medical Center where he was an Assistant Professor, Clinician, and Medical Educator in the Department of Medicine in the Division of Infectious Diseases. Due to his interest in cytokines and immunological responses, Dr. Bonilla became a researcher at ImmunoScience Inc., a biotechnology company in California that works to develop a therapeutic HIV vaccine. Dr. Bonilla’s experience of treating HIV/HCV combined with his interest in inflammatory response is the driving force behind his desire to understand ME/CFS. Dr. Bonilla is a strong patient advocate, and he believes in integrated care—care in which physicians communicate and coordinate efforts to deliver the best medical outcome for patients. His ME/CFS patients are his inspiration, and he is committed to continuing research to seek answers to their health challenges.
-
Kate Bubar
Postdoctoral Scholar, Infectious Diseases
BioKate is a postdoc in the Lo Lab. With a background in applied mathematics, statistics, and infectious disease epidemiology, she is passionate about using data-driven models to better understand infectious disease dynamics with the ultimate goal of informing public health policies and reducing disease burden.
-
Jeffrey Bunker
Fellow in Medicine - Med/Infectious Diseases
BioJeffrey Bunker is an infectious diseases physician-scientist, immunologist, and microbiologist. He is currently a clinical fellow in infectious diseases at Stanford University; he previously completed residency training in internal medicine at Stanford University and an M.D. and Ph.D. in immunology at the University of Chicago. Bunker’s research investigates interactions between the microbiome and the immune system, including fundamental questions about how and why certain microbes generate immune responses and how this interplay influences both normal homeostasis and infectious or inflammatory diseases. His clinical interests include microbial pathogenesis, antimicrobial resistance, and the diagnosis and treatment of complex infections.
-
Joseph David Cooper
Clinical Assistant Professor (Affiliated), Medicine - Med/Infectious Diseases
BioJoseph David Cooper attended Bucknell University for his undergraduate degree with a dual major in Biology and Philosophy. He graduated from St. George’s University School of Medicine and went on to complete his Internal Medicine residency at Geisinger Medical Center in Danville, Pennsylvania. He remained at Geisinger for an additional year as Chief Resident in Internal Medicine with a focus on teaching and the education of trainees. He completed his Infectious Diseases fellowship at Montefiore Medical Center-Albert Einstein College of Medicine in the Bronx, New York. He is board certified in both Internal Medicine and Infectious Disease.
He began working at Santa Clara Valley Medical Center primarily in the PACE (Partners in AIDS Care and Education) and Infectious Diseases Clinics in July 2019. He has an active outreach HIV clinic at Valley Health Center in Gilroy, California once a month which maintains a regional presence for excellence in HIV care. He sees outpatients with general infectious diseases and provides inpatient infectious diseases consultation at Santa Clara Valley Medical Center, the main quaternary referral hospital for the Santa Clara Valley Healthcare system. He is actively involved in the teaching and training of Stanford University Infectious Diseases fellows, Internal Medicine residents from his home institution and Kaiser Permanente Santa Clara. Dr. Cooper holds an appointment of Clinical Assistant Professor (Affiliated) at Stanford University School of Medicine in the division of Infectious Diseases & Geographic Medicine and department of Medicine since 2020.
Dr. Cooper is an active member of the American College of Physicians, WikiGuidelines (PWID and Bacteremia guidelines), Infectious Diseases Society of America, and HIV Medicine Association. He volunteers his time and energy within these international professional organizations previously serving on workgroups surrounding education, mentoring of trainees and as an ad hoc reviewer for infectious diseases and general internal medicine journals. His professional interests are broad and include HIV/AIDS, opportunistic infections, sexually transmitted infections, with a special interest in mycology and fungal infections. He is widely published in a variety of academic journals collaborating with colleagues in all parts of the world. Administratively, Dr. Cooper has held numerous leadership positions, previously serving as Associate Medical Director of the PACE Clinic from 2021 to 2023. Currently, Dr. Cooper holds a leadership position serving on the executive board of Valley Physicians Group (VPG), an organization representing over 400 physicians, dentists and podiatrists at his current institute, focusing on physician advocacy, excellence and organization. Dr. Cooper is passionate about providing high quality, evidence-based care to people living with HIV and AIDS. He uses his professional expertise, passion and energy to ensure that his patients remain as well and healthy as possible.
Outside of medicine and work, you can find Dr. Cooper spending time with his wife and two daughters - hiking and exploring the Bay Area and beyond, listening to all types of music with a particular interest in live music, gardening, nature photography, cooking new recipes, exercising and playing sports.
